title: Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.
abstract: OBJECTIVE
  IgH gene rearrangement studies with a polymerase chain reaction (PCR) technique can detect the persistence of clonal cells at molecular level during the remission phase. This persistence of clonal cells can be used to establish the relationship between minimal residual disease (MRD) and clinical outcome. We have developed a three-step single strand conformational polymorphism PCR strategy which is able to detect clonal B lymphoid cells at a frequency as low as 1 clonal cell in 10(6) normal cells.
  
  
  METHODS
  Twenty patients with intermediate or high-grade B non-Hodgkin's lymphoma (NHL) were evaluated. Patients were pre-treated with a median of two (range 1-4) conventional chemotherapy lines before high-dose cyclophosphamide (HDCY). All patients had their bone marrow (BM) involved by disease (median 10%; range 5-50%). Nineteen patients were offered high-dose therapy followed by peripheral blood progenitor cells (PBPC) autografting.
  
  
  RESULTS
  MRD analysis was performed for each patient at the end of conventional chemotherapy and every three months after high dose therapy. All these patients achieved complete response (CR) after high dose therapy (HDT). Six patients relapsed after a median time of 24.5 months. All the studied apheresis samples were positive at the molecular analysis. All 6 patients still positive at the molecular analysis after PBPC autografting relapsed. The remaining 13 patients who were negative maintained CR.
  
  
  CONCLUSIONS
  Whereas the detection of clonal cells in the apheresis samples did not predict an unfavorable outcome, the disappearance of the clonal rearranged band from the BM sample after HDT proved to be a favorable prognostic factor and was associated with long-lasting disease-free status
authors.affiliation: Department of Internal Medicine, Azienda Ospedale S. Martino e Cliniche Universitarie convenzionate, Genoa, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Miglino
authors.forename: G
authors.initials: G
authors.lastname: Santini
authors.forename: R
authors.initials: R
authors.lastname: Grasso
authors.forename: D
authors.initials: D
authors.lastname: Pietrasanta
authors.forename: M
authors.initials: M
authors.lastname: Clavio
authors.forename: I
authors.initials: I
authors.lastname: Pierri
authors.forename: L
authors.initials: L
authors.lastname: Canepa
authors.forename: S
authors.initials: S
authors.lastname: Nati
authors.forename: F
authors.initials: F
authors.lastname: Ballerini
authors.forename: R
authors.initials: R
authors.lastname: Varaldo
authors.forename: G
authors.initials: G
authors.lastname: Palmisano
authors.forename: M
authors.initials: M
authors.lastname: Gobbi
mesh_terms: D000328:Adult; D001853:Bone Marrow / Q000473:pathology*; D005260:Female; D015321:Gene Rearrangement; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D007143:Immunoglobulin Heavy Chains